hers semaglutide fda Hims & abandons copycat weight-loss drug in face of probe FDA Blocks Hims & Hers

In individuals with obesity, at a daily dose of 50 mg, it achieved a 17.4% reduction in body weight over 68 weeks of treatment in the OASIS 1 trial37 (Table 1), attributed to its appetite-suppressing and satiety-enhancing effects

Metabolism, hormones, insulin resistance, inflammation, and genetics all play major roles

What are the long-term benefits of GLP-1s

Archived from the original on 24 June 2007

Using non-bacteriostatic water significantly increases contamination risk

the label assigns weight-management and cardiovascular-risk indications to the tablets, while the accelerated-approval MASH indication applies to the injection